Current Edition

Disease

Scientists home in on cause of Duchenne gene therapy side effect

Duchenne muscular dystrophy, a degenerative disease mostly affecting young boys, is one of the top targets for gene therapy developers. Recently, however, the pace of …

Continue Reading →
Alzheimer

Biogen CEO to step down as company pulls back from Alzheimer’s drug

Biogen is searching for a new CEO along with additional ways to cut costs after another quarter of paltry sales for its closely watched Alzheimer’s …

Continue Reading →
ALS

FDA advisers narrowly side against an experimental ALS drug, likely lowering its approval chances

By a slim margin, advisers to the Food and Drug Administration have concluded that the agency should hold off approving a closely watched, experimental medicine …

Continue Reading →
Boehringer

With trial success in kidney disease, Lilly, Boehringer make case for broader use of diabetes drug

Dive Brief: Eli Lilly and Boehringer Ingelheim’s drug Jardiance kept clinical trial participants with kidney disease from needing dialysis or a transplant, the companies announced …

Continue Reading →
Disease

Roche revives a closely watched Huntington’s disease drug

Dive Brief: Roche has outlined a new clinical path forward for a closely watched Huntington’s disease drug ten months after disappointing Phase 3 study results …

Continue Reading →
Alzheimer

Aftershocks for Lilly, CRISPR versus CRISPR and Bluebird’s crucial year

The biggest industry news of the week came not from the J.P. Morgan Healthcare Conference or any associated announcements, but from Washington, D.C, where the …

Continue Reading →
cancer

Novartis hits another setback in plan to repurpose rare disease drug in lung cancer

Novartis’ testing of canakinumab, which works by curbing inflammatory signaling in cells, for the seemingly unrelated use in lung cancer stems from an intriguing 2011 …

Continue Reading →
COVID-19

Shoring up Diagnostics Manufacturing for the Next Pandemic

As the global response to COVID-19 continues to move from a state of national lockdowns to the re-opening of societies, diagnostic assay developers are confronting …

Continue Reading →